









Fig. 1












1000, 800, 600, 400, 300, 200, 100, 50, 25°C









F(6.2)








115 β







TOEFL 2650

















Fig. 5






F.C.J






I




III




IV


II




V



VI




VII




VIII




IX




X




XI




XII




XIII




XIV




XV




XVI




XVII



XVIII











XIX




XX

FIG. 9





XLVII



XLVIII











FIG. II




LV




LXI




LXII




LXIII




LXIV




LXV



LXVI




LXVII




LXVIII

FIG. 12




LXIV




LXV




LXVI




LXVII




LXVIII




LXIX




LXX




LXXI



LXXII




LXXIII




LXXIV


FIG. 13



LXXV



LXXVI



LXXVII

FIG. 14




FIGURE 15

RANTES (80ng/ml) binding inhibition
with heparin in Elisa




FIGURE 16

ELISA


RANTES (80ng/ml) binding
inhibition

FIGURE 17

ELISA

RANTES (80ng/ml) binding
inhibition




FIGURE 18

ELISA
Eotaxin (80ng/ml) binding inhibition




FIGURE 19

ELISA

IL-8 (80ng/ml) binding
inhibition




FIGURE 20

ELISA RANTES (80ng/ml) binding inhibition
with compound




FIGURE 21

ELISA

IL-8 (80ng/ml) binding inhibition
with compound




FIGURE 22

ELISA

Binding inhibition




FIGURE 23

ELISA

EOTAXIN (80ng/ml) binding
inhibition




FIGURE 24

Y026007-84110/2660

ELISA

EOTAXIN (80ng/ml) binding
inhibition




FIGURE 25

ELISA

EOTAXIN (80ng/ml) binding
inhibition




FIGURE 26

ELISA
RANTES (80ng/ml) binding inhibition
with compounds




FIGURE 27

ELISA IL-8 (80ng/ml) binding inhibition
with compounds




FIGURE 28